Pfizer's Hospira recalls 3 drug lots over particulate concerns

Hospira, a unit of Pfizer, issued a voluntary recall of sodium bicarbonate and lidocaine HCI injectables due to the possible presence of glass particles in the vials.

Monday, Hospira said it recalled one lot of 4.2% sodium bicarbonate injection with an August 2024 expiration date. The company also recalled a 1% lidocaine HCI injection lot with a June 2024 expiration date and a 2% lidocaine HCI injection lot with a July 2024 expiration date.

Hospira's notice was posted on the FDA's website.

The products were distributed nationwide and in the U.S. territory of Puerto Rico last October. The company said there have been no reports of adverse events related to the products.

Sodium bicarbonate injection is typically used to treat metabolic acidosis resulting from severe renal disease, uncontrolled diabetes, cardiac arrest or other serious health complications.

Lidocaine HCI injection is used as an anesthetic for patients undergoing certain medical procedures plus acute management of ventricular arrhythmias.

Hospira has weathered its share of manufacturing issues and recalls over the years.

In late 2022, the company recalled one lot of its vancomycin hydrochloride injection vials because of glass particles in the vials. In July the same year, the company recalled one lot of the anesthetic propofol after an employee found “a visible particulate” in a vial during an annual inspection.

Back in 2017 and 2018, Hospira issued several recalls of injectables due to problems with particulates, microbial growth and a human hair found in a syringe of one lot of 25% dextrose injection for infants.

Pfizer bought Hospira for $17 billion in 2015.